The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Etrion Corporation's Italian solar photovoltaic platform
Advised Etrion Corporation, a solar independent power producer and developer, on the sale of its 60MW Italian solar photovoltaic platform to Ultor S.p.A. (a joint venture owned equally by Enel Green Power S.p.A. and F2i Fondi Italiani per le infrastrutture) for an Enterprise Value of €323mm
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
US rights to Toprol-XL (AstraZeneca)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
Texas Competitive Electric Holdings and its subsidiaries
Advised Texas Competitive Electric Holdings, Texas’ largest power generator and competitive retail electricity provider, and its subsidiaries at the direction of its independent director in connection with its and Energy Future Holdings’ Chapter 11 proceedings
Whistler Blackcomb Holdings Inc.
Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.
BioD, LLC
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
Aegerion Pharmaceuticals
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
Apex International Energy Management LLC
Advised Apex International Energy Management, a newly formed oil and gas venture focused on the Middle East and North Africa regions, in the private equity fund-raising process with multiple energy-focused financial sponsors, ultimately resulting in an initial $500 million capital commitment from Warburg Pincus.
Equinix Data Center Assets
Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix
Brasil/CT
Advised Brasil/CT on a capital injection made by Invest Tech in the Company. Brasil/CT specializes in the e-commerce market and is a leader in B2C and B2B full-commerce and loyalty operations in Brazil. Invest Tech is an investment manager focused on venture capital and private equity in the technology and telecom sectors
Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
Broadcom’s Wireless Internet of Things (IoT) Business Unit
Advised Cypress Semiconductor, a leading provider of high-performance, mixed-signal, programmable solutions worldwide, on its acquisition of Broadcom’s Wi-Fi, Bluetooth and ZigBee product lines for automotive, industrial and consumer IoT markets
Elavon do Brasil
Advised Minneapolis-based US Bancorp, the fifth largest commercial bank in the United States, and the parent company of Elavon, Inc., in the sale of its 50.1 percent majority stake in São Paulo-based, Elavon do Brasil to Stone Pagamentos, a local market, privately-held merchant acquirer.
Total Care Medicaid Plan
Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan
Rofin-Sinar Technologies, Inc.
Advised Rofin-Sinar Technologies, Inc., a leading manufacturer of industrial laser sources and laser-based solutions and components, on its sale to Coherent, Inc., a leading provider of lasers and laser-based technology for scientific, commercial and industrial customers
Boehringer Ingelheim
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
Policard
Advised Policard, one of the largest electronic payment companies in Brazil, on the combination of its business with the Brazilian operations of Groupe Up, one of the leading employee benefits, public, social and loyalty programs providers in the world
Antin Solar Investments
Advised Antin Infrastructure Partners on its sale of Antin Solar Investments, a leading Italian solar platform, to a consortium of investors comprised of Swiss Life Asset Management and Quercus Investment Partners